Literature DB >> 12483106

Regulation of neutrophil function by Rac GTPases.

Mary C Dinauer1.   

Abstract

Rac plays a central role in regulating neutrophil responses to inflammatory signals, including actin remodeling, chemotaxis, and superoxide production by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Rac-GTP is a component of the membrane-assembled NADPH oxidase complex, and new evidence suggests that Rac-GTP interacts directly with the oxidase flavocytochrome, in addition to binding to the regulatory p67 subunit, to regulate electron transfer both independently and cooperatively from NADPH to molecular oxygen. Other new studies suggest that Rac-GTP plays a dual role in NADPH oxidase activation, and can initiate signaling pathways leading to translocation of cytosolic oxidase subunits in addition to functioning in the assembled enzyme complex. Rac activation in response to neutrophil chemoattractants may be regulated in large part by a newly identified guanine nucleotide exchange factor, P-Rex1, which is activated by either phosphatidylinositols or Gbetagamma subunits. Multiple Rac GTPase activating proteins are present in neutrophils and may also modulate levels of Rac-GTP. The importance of Rac in a broad range of neutrophil functions is shown by the variety of defects seen in neutrophils from Rac2 knockout mice and from a patient with recurrent infections and a dominant-negative mutation in Rac2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12483106     DOI: 10.1097/00062752-200301000-00003

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  37 in total

1.  p21-activated kinase (Pak) regulates NADPH oxidase activation in human neutrophils.

Authors:  Kendra D Martyn; Moon-Ju Kim; Mark T Quinn; Mary C Dinauer; Ulla G Knaus
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

2.  Phagocyte cell migration is mediated by phospholipases PLD1 and PLD2.

Authors:  Nicholas Lehman; Mauricio Di Fulvio; Nicholas McCray; Isabel Campos; Farnaz Tabatabaian; Julian Gomez-Cambronero
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

Review 3.  New players in TLR-mediated innate immunity: PI3K and small Rho GTPases.

Authors:  Monica Ruse; Ulla G Knaus
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Fungal metabolite gliotoxin targets flavocytochrome b558 in the activation of the human neutrophil NADPH oxidase.

Authors:  Satoshi Nishida; Lucia S Yoshida; Takashi Shimoyama; Hiroyuki Nunoi; Toshihiro Kobayashi; Shohko Tsunawaki
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 5.  Small Rho GTPases in the control of cell shape and mobility.

Authors:  Arun Murali; Krishnaraj Rajalingam
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

Review 6.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

7.  Rac GTPases play multiple roles in erythropoiesis.

Authors:  Peng Ji; Harvey F Lodish
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

Review 8.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

Review 9.  Rho GTPases in hematopoiesis and hemopathies.

Authors:  James C Mulloy; Jose A Cancelas; Marie-Dominique Filippi; Theodosia A Kalfa; Fukun Guo; Yi Zheng
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

10.  TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway.

Authors:  Honghong Sun; Guohong Zhuang; Lihui Chai; Zhaojun Wang; Derek Johnson; Yuanfang Ma; Youhai H Chen
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.